Commencement of Commercial Production at Unit-II of Asston Pharmaceuticals Limited.

Greenfield CommissionedCapex & Operations View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹85.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.6%-1.3% vs market

Pharmaceuticals peers, median of 156sector+1.2%-1.0% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+1.6-1.3+1.2-1.0

Next day

+0.4-0.6+1.0+0.0+0.4

+1.2-0.5+1.7-0.7+1.8

+1.4+1.5-0.2+0.2+1.2

-4.5+1.1-5.6-0.3-4.2

-2.4+3.0-5.3+0.2-2.6

-5.9+5.5-11.4+2.4-8.3

15d

—+6.1—+2.7—

—+5.1—+1.3—

-19.8-8.0-11.9-8.2-11.6

-8.2+10.9-19.2+3.5-11.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Asston Pharmaceuticals Limited has commenced commercial production at its Unit-II manufacturing facility located at MIDC, Additional Ambernath, Anand Nagar Industrial Area, Dist-Thane, Maharashtra, effective January 21, 2026. The unit manufactures pharmaceutical and nutraceutical products. This follows the company's earlier communication dated November 14, 2025 regarding capacity addition, and the company states the commissioning has happened 'as per the scheduled plan.' Unit-II is described as a new manufacturing unit being brought online.

Likely market impact

This is a positive development as it expands the company's manufacturing capacity for pharmaceuticals and nutraceuticals, potentially enabling higher revenues and market reach. Shareholders should watch for incremental order wins and revenue contribution from Unit-II in upcoming quarterly results.